New cancer drug targets genetic weakness in advanced tumors

NCT ID NCT03993873

Ongoing Disease control Sponsor: Turning Point Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing a new oral drug called TPX-0022 (elzovantinib) in adults with advanced or spreading cancers that have specific changes in the MET gene. The study aims to find the safest and most effective dose while checking if the drug helps control tumors in lung cancer, stomach cancer, and other solid tumors. Participants will take the drug continuously as long as it helps control their cancer and they can tolerate it.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Local Institution - 2101

Houston, Texas, 77030-4009, United States
Local Institution - 2102

La Jolla, California, 92093, United States
Local Institution - 2103

St Louis, Missouri, 63110, United States
Local Institution - 2104

Toledo, Ohio, 43614, United States
Local Institution - 2105

Denver, Colorado, 80218, United States
Local Institution - 2106

Ann Arbor, Michigan, 48109, United States
Local Institution - 2107

Boston, Massachusetts, 02114, United States
Local Institution - 2108

Orange, California, 92868, United States
Local Institution - 2109

Boston, Massachusetts, 02215, United States
Local Institution - 2111

Chicago, Illinois, 60637, United States
Local Institution - 2112

Fairfax, Virginia, 22031, United States
Local Institution - 2113

Detroit, Michigan, 48202, United States
Local Institution - 4101

Madrid, 28050, Spain
Local Institution - 4102

Pamplona, 31008, Spain
Local Institution - 4103

Madrid, 28040, Spain
Local Institution - 4104

Madrid, 28036, Spain
Local Institution - 4201

Lyon, 69008, France
Local Institution - 4202

La Tronche, Auvergne-Rhône-Alpes, 38700, France
Local Institution - 4203

Saint-Mandé, Val-de-Marne, 94160, France
Local Institution - 4204

Villejuif, Val-de-Marne, 94805, France
Local Institution - 6301

Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea
Local Institution - 6302

Seoul, 120-752, South Korea
Local Institution - 6303

Seoul, 03080, South Korea
Local Institution - 6304

Seoul, 05505, North Korea

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR MET GENE ALTERATIONS METASTATIC SOLID TUMORS